Dyadic International (DYAI) Gets a Buy Rating from Noble Financial


In a report issued on February 20, Ahu Demir from Noble Financial maintained a Buy rating on Dyadic International (DYAI), with a price target of $4. The company’s shares closed on Friday at $2.85, close to its 52-week high of $2.91.

Demir has an average return of 47.6% when recommending Dyadic International.

According to TipRanks.com, Demir is ranked #3224 out of 5205 analysts.

Dyadic International has an analyst consensus of Moderate Buy, with a price target consensus of $4.

See today’s analyst top recommended stocks >>

Based on Dyadic International’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $1.54 million. In comparison, last year the company had a GAAP net loss of $1.37 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dyadic International, Inc. operates as a biotechnology company. It uses its patented and proprietary technologies for the discovery, development, manufacture, and sale of enzymes and other proteins for the bioenergy, biochemical, biopharmaceutical, and industrial enzyme industries.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts